DNA Diagnostics Market Analysis By Technology (Microarray Based, PCR Based, In-situ Hybridization, NGS DNA Diagnosis), By Application (Pre-natal DNA Carrier Screening, Pre-implantation Diagnosis, Newborn Genetic Screening, Infectious Disease Diagnostics (HBV, HCV, HIV, TB, CT/NG, HPV, & MRSA), Oncology Diagnostics & Histopathology, Identity Diagnostics & Forensics, Pharmacogenomics Diagnostic Testing, & Drug Metabolism/P450 Effects), And Segment Forecasts To 2022
- Report ID: 978-1-68038-676-9
- Number of Pages: 148
- Format: Electronic (PDF)
- Historical Data: 2013-2015
- Industry:Healthcare
Market Segmentation
Global DNA Diagnostics/Testing Technology Outlook (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
Global DNA Diagnostics/Testing Application Outlook (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- Global DNA Diagnostics/Testing Regional Outlook (Revenue, USD Million, 2012 - 2022)
- North America
- U.S.
- U.S. DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- U.S. DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- U.S. DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Canada
- Canada DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- Canada DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- Canada DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- U.S.
- Europe
- Germany
- Germany DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- Germany DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- Germany DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- UK
- UK DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- UK DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- UK DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Germany
- Asia Pacific
- Japan
- Japan DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- Japan DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- Japan DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- China
- China DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- China DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- China DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Japan
- Latin America
- Brazil
- Brazil DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- Brazil DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- Brazil DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Mexico
- Mexico DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- Mexico DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- Mexico DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Brazil
- MEA
- South Africa
- South Africa DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- Microarrays based diagnostics
- PCR based diagnostics
- In-situ hybridization diagnostics
- NGS DNA diagnosis
- South Africa DNA Diagnostics/Testing, by Application (Revenue, USD Million, 2012 - 2022)
- Prenatal DNA Carrier Screening
- Preimplantation Diagnosis
- Newborn Genetic Screening
- Infectious Disease Diagnostics
- HBV Diagnostic
- HCV Diagnostic
- HIV Diagnostic
- TB Diagnostic
- CT/NG Diagnostic
- HPV Diagnostic
- MRSA Diagnostic
- Others
- Oncology Diagnostics & Histopathology
- Identity Diagnostics & Forensics
- Pharmacogenomics Diagnostic Testing
- Drug Metabolism & P450 effects
- Others
- South Africa DNA Diagnostics/Testing, by Technology (Revenue, USD Million, 2012 - 2022)
- South Africa
- North America
Report Content
Qualitative Analysis
- Industry overview
- Industry trends
- Market drivers and restraints
- 乐鱼体育手机网站入口
- Growth prospects
- Porter’s analysis
- PESTEL analysis
- Key market opportunities prioritized
- Application Segments Prioritized
- Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments
Quantitative Analysis
- Market size, estimates, and forecast from 2012 to 2022
- Revenue estimates for technology up to 2022
- Regional market size and forecast for technology up to 2022
- Revenue estimates for application up to 2022
- Regional market size and forecast for application up to 2022
- Company financial performance
GET A FREE SAMPLE
这个免费样品包括市场数据点,响了ing from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report -free of charge- including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us nowto get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read ourprivacy policy.
